Clinical trials: Cardio-oncology
Cardiac Disease, Cancer
Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)
Antineoplastic and immunomodulating agents may lead to various cardio-vascular adverse reactions. This study investigates reports of cardio-vascular toxicities for treatment including Anatomical Therapeutic Chemical (ATC)…
- Trial name
- EROCA (NCT03530215)
- Testing
- Antineoplastic and Immunomodulating Agents
- Where
- France
- Volunteers
- 500,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Cancer
Glasgow Low-dose CT and AI-based Diagnostics to Case Find Lung Cancer and Other Cardio-respiratory Long-term Conditions - Feasibility Study
Lung cancer is one of the most common and serious cancers in Scotland and is often diagnosed at a late stage. Early detection is crucial to improving survival rates.
- Trial name
- GALACTIC-1 (NCT07372508)
- Testing
- Low dose Chest CT
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- NHS Greater Glasgow and Clyde
Childhood Cancer
Cardiopulmonary Fitness and Its Clinical Determinants of a Population of Childhood Cancer Survivor
Medical progress have made it possible to considerably improve the survival of children with an oncological disease. Currently, the survival rate increased to above 90 % in the most developed countries .
- Trial name
- ONCO-SPORT (NCT04815447)
- Where
- France
- Volunteers
- 500 people
- Sponsor
- University Hospital, Montpellier
Hematopoietic Stem Cell Transplant
Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation
To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing…
- Trial name
- NCT05945121
- Testing
- Cardio-oncology program
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Michigan Rogel Cancer Center
Cardiovascular Complication, Cardiovascular Insufficiency
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer…
- Conditions
- Cardiovascular Complication, Cardiovascular Insufficiency, Cardiac Complication, Oncologic Complications
- Trial name
- NEOCARDIO (NCT03882580)
- Testing
- Anti-Cancer Agents
- Where
- 3 sites in France
- Volunteers
- 5,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Head and Neck Cancer
Bleeding, Cardio- and Cerebrovascular Complications in Head and Neck Surgery
In this retrospective registry trial, the investigators sought to assess the incidence and predictors of cardiovascular and cerebrovascular complications as well as their derivatives (acute coronary syndrome, decompensated heart…
- Trial name
- NCT02563470
- Volunteers
- 456 people
- Sponsor
- University of Turku
Breast Cancer
Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity
The purpose of this study is to evaluate whether dapagliflozin reduces chemotherapy-induced cardiotoxicity in participants with breast cancer treated with (neo-)adjuvant Anthracycline-based chemotherapy +/- trastuzumab.
- Trial name
- PROTECT (NCT06341842)
- Testing
- Dapagliflozin 10mg Tab
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Cancer, Cardiac Disease
Cardio-Oncology Registry
Cardio-oncology is an emerging field. Most of the data available have been issued from either retrospective analysis, industry data or pharmacovigilance data. These data sources include a number of bias.
- Conditions
- Cancer, Cardiac Disease, Metabolic Syndrome, Arrhythmia
- Trial name
- CONFUCIUS (NCT04407780)
- Testing
- No interventions are planned
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- European Georges Pompidou Hospital
ACS - Acute Coronary Syndrome, Oncology
The BRAvAdO Registry
The BRAVADO Registry pretends to identify stratification, diagnosis, total atherosclerotic burden and treatment approaches in oncologic patients with Acute Coronary Syndrome (ACS) and identify strategies to improve health care…
- Trial name
- BRAvAdO (NCT04222608)
- Where
- Brazil
- Volunteers
- 600 people
- Sponsor
- University of Sao Paulo General Hospital
Empgliflozin Cardioprotective Effect
Cardioprotective Effect of Empagliflozin in Breast Cancer Patients
Background: Doxorubicin (DOX) remains a cornerstone in adjuvant and neoadjuvant therapy for breast cancer, but its utility is hindered by dose-dependent cardiotoxicity.
- Trial name
- NCT07815808
- Testing
- Empagliflozin (EMPA), Metformin
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Tanta University
Cancer Survivors, Cardiotoxicity
In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors
The BREATHS trial aims to investigate whether overnight in-bedroom air filtration reduces inflammation and cardiac biomarkers in adult survivors of cancer who are at high risk for cardiovascular complications.
- Conditions
- Cancer Survivors, Cardiotoxicity, Cardiovascular Toxicity Induced by Antitumoral Drugs
- Trial name
- BREATHS (NCT06778122)
- Testing
- High efficiency particulate air filtration system (nightly administration), High efficiency particulate air filtration system (nightly and daily administration)
- Where
- 3 sites in Spain
- Volunteers
- 10 people
- Sponsor
- University College, London
Degradation of Top2b and Top2a in Human by Dexrazoxane, Time Course and Degradation of Top2b in Human by Dexrazoxane
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
The purpose of this research study is to determine whether early administration of Dexrazoxane prevents Doxorubicin induced cardiotoxicity.
- Conditions
- Degradation of Top2b and Top2a in Human by Dexrazoxane, Time Course and Degradation of Top2b in Human by Dexrazoxane, Effects of Dexrazoxane on Healthy Human
- Trial name
- PHOENIX1 (NCT03930680)
- Testing
- Dexrazoxane
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Cardiotoxicity, Anthracycline Related Cardiotoxicity in Breast Cancer
ANTthracycline-induced Inflammation and OXidative Stress: 10-year Follow-up
The goal of this observational study is to learn about the long-term effects of anthracycline chemotherapy on inflammation, oxidative stress, and heart function in adult women with breast cancer.
- Conditions
- Cardiotoxicity, Anthracycline Related Cardiotoxicity in Breast Cancer, Breast Cancer
- Trial name
- ANTIOX-10 (NCT07680855)
- Volunteers
- 17 people
- Sponsor
- University of Chile
Cancer
Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial
The purpose of this study is to examine adherence to cardio-oncology consultation.
- Trial name
- CARMA (NCT05403736)
- Testing
- Cardiac Aggressive Risk MitigAtion Plan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Cardiotoxicity, Heart Failure
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
Cancer treatments have improved substantially over the past decades, but some effective therapies such as anthracyclines and HER2-targeted agents are associated with severe cardiovascular adverse effects, including heart failure.
- Conditions
- Cardiotoxicity, Heart Failure, Neoplasms, Breast Neoplasms
- Trial name
- ML-CardioTox (NCT07191730)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Caen
Breast Cancer, Cardiotoxicity
Cardiotoxicity in Breast Cancer Patients Treated With Proton or Photon Radiotherapy: A RadComp Companion Study
This is a companion study to the "Pragmatic Randomized Trial of Proton vs Photon Therapy for Patients with non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RadComp)…
- Trial name
- NCT04361240
- Testing
- Proton vs Photon Radiation
- Where
- 6 sites in United States
- Volunteers
- 172 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cancer, Breast, Cardiotoxicity
Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2)
Although great progress has been made in treating breast cancer, long-term health may be impaired by cancer therapy. For example, some chemotherapy drugs (e.g., anthracyclines) are known to cause declines in heart health.
- Conditions
- Cancer, Breast, Cardiotoxicity, Cardiovascular Diseases
- Trial name
- EXACT2 (NCT03748550)
- Testing
- Aerobic exercise
- Where
- 2 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Nova Scotia Health Authority
Multimorbidity, Cancer
The LifeMeds Cohort
The goal of this observational study is to investigate lifestyle behaviours, their determinants, and their associations with health outcomes in adults with multimorbidity, defined as the presence of at least two lifestyle-related…
- Conditions
- Multimorbidity, Cancer, Cardio Vascular Disease, Chronic Respiratory Conditions
- Trial name
- LifeMeds (NCT07846800)
- Volunteers
- 2,000 people
- Sponsor
- Tilburg University
Breast Cancer Female, Adriamycin Toxicity
Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.
This research is being done to determine whether exercise while receiving doxorubicin or Adriamycin chemotherapy for breast cancer can reduce the cardio-toxic effects of this treatment on the heart and improve other outcomes…
- Trial name
- NCT03027063
- Testing
- 10,000 steps, Usual Care
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Johns Hopkins University
Breast Cancer Survivorship
Exercise to Improve Neurovascular Function in Breast Cancer Survivors
Study Rationale: Breast cancer survivors are more likely to develop cardiovascular disease (CVD) or neurocognitive disease than age-matched counterparts without a history of cancer diagnosis.
- Trial name
- PIONEER (NCT06925529)
- Testing
- Cardio-Oncology Rehabilitation and Exercise Programme
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Baker Heart and Diabetes Institute